Meet the pace of new scientific applications and technological advances with inside knowledge from CAP18 industry partners. Gain a unique perspective to avoid the pitfalls and boost success when applying these emerging sciences to practical reality from some of those on the front lines. A complimentary meal will be provided during these events.

The CAP does not endorse the content of the industry workshops, individual presenters, or sponsoring companies.

Sunday, October 21

CAP State Pathology Society Breakfast Workshop — Growing Membership in Your State Pathology Society

Presenter: Bekra Yorke, MD and Mathew R. Foster, MD, FCAP

Sunday, October 21
6:45–7:45 AM
CME/CE NOT APPLICABLE

Looking for guidance to make your state society healthier? Hear from leaders of two active state pathology societies sharing membership strategies they use. Remember that when working with elected officials, the number of members in an organization affects its ability to impact decisions and guide policy.

Presenter
Bekra Yorke, MD
President, Texas Society of Pathologists
Cypress Fairbanks Medical Center
Houston, Texas

Mathew R. Foster, MD, FCAP
President, Virginia Society for Pathology
Pathology Consultants of Central Virginia
Lynchburg, Virginia

IWSL800 Complimentary Industry Lunch Workshop — Tissue Stewardship in the Age of Comprehensive Biomarker Testing in Non-Small Cell Lung Cancer (NSCLC)

Presenter: John Longshore, PhD, FACMG, Carolinas Pathology Group

Presented by: AstraZeneca

Sunday, October 21
11:45 AM–1:15 PM
CME/CE NOT APPLICABLE

This pathologist-delivered program highlights the importance of good tissue stewardship for performing comprehensive biomarker testing and providing quality care to patients with NSCLC.

Presenter
John Longshore, PhD, FACMG, Carolinas Pathology Group

The CAP does not endorse the content of the industry workshops, individual presenters, or sponsoring companies.

IWSL801 Complimentary Industry Lunch Workshop — Checkpoint Inhibitors and Beyond PD-L1 IHC: A Pathology Primer on Immunomodulatory Immunotherapeutics

Speaker: Carl Morrison, MD, FCAP – President, CMO & Founder, OmniSeq Inc.

Integrated Oncology

Sunday, October 21
11:45 AM–1:15 PM
CME/CE NOT APPLICABLE

Over just the past three years, the use of immunotherapies has advanced to a level equal to or surpassing that for targeted therapies. For immunotherapy the concept of precision medicine is not mutation based, but rather expression based similar to HER-2 and trastuzuamb. Most notable among these immunotherapy associations is PD-L1 expression for PD-1 axis checkpoint inhibitors such as pembrolizumab or nivolumab.  Currently over 100 unique immunotherapies with specific associations with immune-related targets are under clinical investigation.This presentation will provide an introduction into this new world of immunomodulatory immunotherapeutics and provide a simplified framework for classification of this field from a pathologist’s perspective.  

Speaker
Carl Morrison, MD, FCAP – President, CMO & Founder, OmniSeq Inc.

The CAP does not endorse the content of the industry workshops, individual presenters, or sponsoring companies.

IWSL802 Complimentary Industry Lunch Workshop — Concordance Between an Automated, Ready-to-Use MMR IHC Panel and Next-Generation Sequencing for Identification of MMR Status and BRAF V600E Mutations in Colorectal Cancer

Presenter: Shalini Singh, MD, Senior Director, Pathology Office, Ventana Medical Systems, Inc. and
Eric Konnick, MD, University of Washington

Presented by: Roche

Sunday, October 21
11:45 AM–1:15 PM
CME/CE NOT APPLICABLE

The importance of MMR testing is highlighted by changes in clinical practice guidelines and recent news regarding other emerging utilities. This session will discuss the agreement between IHC and molecular testing using a fully automated, ready-to-use MMR IHC panel that includes BRAF V600E IHC, which is concordant, versus molecular methods (including NGS) for the identification of dMMR/pMMR CRC cases.

Presenter
Shalini Singh, MD, Senior Director, Pathology Office, Ventana Medical Systems, Inc.
Eric Konnick, MD, University of Washington

The CAP does not endorse the content of the industry workshops, individual presenters, or sponsoring companies.

IWSL803 Complimentary Industry Lunch Workshop — Updates on Vulvar Intraepithelial Neoplasia and Squamous Carcinoma and Ovarian Serous Borderline Tumors: Classification, Differential Diagnosis, and Staging

Presenter: Jesse McKenney, MD and Bin Yang, MD, PhD

Presented by: Cleveland Clinic Laboratories

Sunday, October 21
11:45 AM–1:15 PM
CME/CE NOT APPLICABLE

Presenter
Jesse McKenney, MD
Bin Yang, MD, PhD

The CAP does not endorse the content of the industry workshops, individual presenters, or sponsoring companies.

IWSL804 Complimentary Industry Lunch Workshop — Comprehensive Genomic Profiling becoming a new Standard-of-Care in Oncology

illimina

Sunday, October 21
11:45 AM–1:15 PM
CME/CE NOT APPLICABLE

The value behind a comprehensive assessment of the genomic alterations in a tumor has been consistently increasing with the availability of new therapeutic agents and better predictability of response. The regulatory and reimbursement for this type of assay evolved drastically over the last years. We will discuss how this change in environment provides strong value to adopt comprehensive genomic profiling in today’s oncology care.

The CAP does not endorse the content of the industry workshops, individual presenters, or sponsoring companies.

Monday, October 22

IWML806 Complimentary Industry Lunch Workshop — NSCLC Testing Modalities, Clinical Relevance, and Guidelines: ALK as a Predictive Biomarker and EGFR and PD-L1 Diagnostic Methods

Presented by Roche
Presenter: Anjali Saqi, MD, Professor of Pathology & Cell Biology, Columbia University Medical Center, New York City and 
John W. Longshore, PhD, Director of Molecular Pathology, Carolinas Pathology Group, Charlotte, North Carolina

Monday, October 22
11:45AM–1:15 PM

Join us to learn the importance of ALK testing and testing modalities in non-small cell lung cancer (NSCLC) and review the latest testing guidelines. The session will also review the latest testing guidelines and methodologies for EGFR and PD-L1.

Presenter
Anjali Saqi, MD
Professor of Pathology & Cell Biology, Columbia University Medical Center, New York City

John W. Longshore, PhD
Director of Molecular Pathology, Carolinas Pathology Group, Charlotte, North Carolina

The CAP does not endorse the content of the industry workshops, individual presenters, or sponsoring companies.

IWML807 Complimentary Industry Lunch Workshop — Implementation of Digital Pathology in a National Clinical Reference Lab

Philips

Monday, October 22
11:45AM–1:15 PM

The CAP does not endorse the content of the industry workshops, individual presenters, or sponsoring companies.

IWML808 Complimentary Industry Lunch Workshop — Advancing Precision Oncology: Current and Emerging Biomarkers and Pharmacodiagnostic Tools

Bristol-Myers-Squibb

Monday, October 22
11:45 AM–1:15 PM
CME/CE NOT APPLICABLE

The use of biomarkers in cancer treatment has allowed for increased patient segmentation. This has been enabled by advances in development of new biomarkers that allow for further characterization of the tumor microenvironment. This talk will focus on ongoing use of current and emerging biomarkers and use of composite biomarkers as pharmacodiagnostic tools that are paving the path towards precision medicine.

The CAP does not endorse the content of the industry workshops, individual presenters, or sponsoring companies.

IWML809 Complimentary Industry Lunch Workshop — Comprehensive Genomic Profiling in Tissue and Liquid: Overview, Best Practices, and Clinical Utility

Presented by Foundation Medicine

Monday, October 22
11:45 AM–1:15 PM
CME/CE NOT APPLICABLE

Presenter
Presented by Foundation Medecine

The CAP does not endorse the content of the industry workshops, individual presenters, or sponsoring companies.

Tuesday, October 23

IWTB812 Complimentary Industry Breakfast Workshop — The LAST Word: Bringing CERTAINty to Cervical Biopsy Interpretation

Presented by Roche Diagnostics Medical & Scientific Affairs

Tuesday, October 23
7:30–8:45 AM
CME/CE NOT APPLICABLE

Presenter
Presented by Roche Diagnostics Medical & Scientific Affairs

This workshop will focus on the routine use of adjunctive p16 immunohistochemistry in the interpretation of cervical biopsies, based on LAST (Lower Anogential Squamous Terminology) recommendations and the CERTAIN (Cervical Tissue Adjunctive Analysis) study. Staining patterns and interpretation of CINtec Histology will also be discussed.

The CAP does not endorse the content of the industry workshops, individual presenters, or sponsoring companies.

CWTB840 CAP Breakfast Workshop — Establishing Best Practices for Digital Pathology System Interoperability

Presenter: Raj C. Dash, MD, FCAP

Tuesday, October 23
7:30–8:45 AM
CME/CE NOT APPLICABLE

Recent advancements in digital imaging technologies serve to significantly alter traditional workflows within anatomic pathology laboratories. In Europe and Canada with implementations evolving and advancing rapidly, whole slide digital technologies have been leveraged in the past few years to compensate for the shortage of expert pathologists. In the US, the advent of Food and Drug Administration approval of the first whole slide imaging system for primary diagnosis has reignited focus on use cases and value propositions for various vended solutions. However, minimal literature has been published that speaks to optimal interactions amongst current and future vended solutions. The presentation will discuss ongoing efforts underway to address this gap, describe likely scenarios for product development over the next few years, and provide anatomic pathology practices with a better understanding of how and when they might best take advantage of these technologies.

Presenter
Raj C. Dash, MD, FCAP
Duke Health System
Professor and Vice-Chair for IT, Department of Pathology
Director, Laboratory Informatics Strategy & Medical Director, Laboratory Information Systems

CWTB841 CAP Breakfast Workshop — Light-Sheet Microscopy for Slide-Free 3D Digital Pathology

Presenter: Lawrence D. True, MD, FCAP and Nicholas Reder, MD, MPH

Tuesday, October 23
7:30–8:45 AM
CME/CE NOT APPLICABLE

Light-sheet microscopy (LSM) is a fluorescence microscopy technique that produces high-resolution, 3D images. However, commercially available LSM systems are ill-suited for clinical applications. Our engineering-pathology group at the University of Washington created an open-top LSM specifically designed for imaging clinical specimens in 3D (ie, biopsies and surgical resections). We will describe their engineering-pathology collaboration, give a brief overview of the technology, show example use-cases, and explain how this emerging technology could impact the practice of pathology.

Presenter
Lawrence D. True, MD, FCAP
University of Washington Medical Center

Nicholas Reder, MD, MPH
University of Washington Medical Center

IWTB814 Complimentary Breakfast Workshop — Planning for Tomorrow: Estate Planning Workshop

Presented by Fidelity

Tuesday, October 23
7:30–8:45 AM
CME/CE NOT APPLICABLE

Lou Machi, vice president of advanced planning in the Fidelity Wealth Planning and Personal Trust group, will share how a well-crafted estate plan can help you take inventory of your assets now and plan for your family’s financial future. In this estate planning seminar, you will learn about resources to help you manage your assets during your lifetime and provide direction for distribution of assets, including through the use of charitable gifts.

Presenter
Presented by Fidelity

The CAP does not endorse the content of the industry workshops, individual presenters, or sponsoring companies.

IWTL813 – Complimentary Industry Lunch Workshop – Current and Emerging Biomarkers: Science, Technologies, and Practicalities

Bristol-Myers-Squibb

Tuesday, October 23
11:45 AM–1:15 PM
CME/CE NOT APPLICABLE

At Bristol-Myers Squibb, we recognize pathologists play a crucial role in furthering advancements that may help predict which patients are likely to benefit from immuno-oncology therapies.  Join us as we explore one of the hottest topics in molecular pathology: immuno-oncology biomarkers.  Light refreshments will be provided.

The CAP does not endorse the content of the industry workshops, individual presenters, or sponsoring companies.